Implantica announces positive feedback received from U.S. FDA of the RefluxStop™ PMA Module 2 submission
VADUZ, Liechtenstein, Feb. 13, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces that U.S. FDA has completed its review of the PMA Module 2 submission and provided its feedback, in which the company sees no barrier for responding.
FDA has completed its review of the company's second modular submission of its PMA, which contained the Clinical Data, Usability Testing, and Labeling information supporting RefluxStop™. FDA has provided Implantica with its written feedback on the content submitted, all of which the company considers to be minor. A response strategy has been identified for the questions raised, and the company sees no impediment to the overall PMA approval process based on FDA's Module 2 feedback. Responses to the Module 2 feedback will be submitted in conjunction with the final Module 3 submission in the near term.
Dr. Peter Forsell, Implantica's founder, CEO, and the inventor of RefluxStop, says, "We are thankful for FDA for their review of Module 2 and are pleased to receive their positive feedback on our submission thus far. Module 2 includes the results of the RefluxStop™ clinical study and is by far the most important module for this PMA from our perspective. The 5-year outcomes in conjunction with data reported in the literature are extremely positive and indicate that RefluxStop™ may revolutionize this treatment field. Implantica will, in the near term, submit the last component of our PMA application (Module 3) and work with FDA to bring RefluxStop™ to the U.S. market as soon as possible."
For further information, please contact:Nicole Pehrsson, Chief Corporate Affairs OfficerTelephone (CH): +41 (0)79 335 09 49nicole.pehrsson@implantica.com
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company's Certified Adviser is FNCA Sweden AB, info@fnca.se
The information was sent for publication, through the agency of the contact person set out above, on February 13, 2025, at 08:00 a.m. (CET).
About ImplanticaImplantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energizing platform designed to power remote-controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.
About RefluxStop™ RefluxStop™ is a new innovative treatment that has the potential to spur a paradigm shift in anti-reflux surgery. It's unique mechanism of action differentiates it from standard of care and current surgical solutions. Longer established surgical options for GORD involve encircling the food passageway to support the lower oesophageal sphincter's closing mechanism and are commonly associated with side effects such as swallowing difficulties, pain when swallowing and inability to belch and/or vomit.
In contrast, the RefluxStop™ device treats the cause of acid reflux without encircling and putting pressure on the food passageway. It restores and maintains the lower oesophageal sphincter in its original, natural position.
The RefluxStop™ mechanism of action is focused on reconstructing all three components of the anti-reflux barrier, that if compromised could possibly result in acid reflux. It restores and supports the natural anatomical physiology of the body allowing the body to itself solve the problem with acid reflux.
Newsroomhttps://www.implantica.com/media/media-kit
Communityhttps://ch.linkedin.com/company/implanticahttps://www.twitter.com/implantica
Media Contact:Implantica AGJuanita Eberhart, VP Marketing & AdvocacyM: +1 925-381-4581juanita.eberhart@implantica.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/implantica/r/implantica-announces-positive-feedback-received-from-u-s--fda-of-the-refluxstop--pma-module-2-submis,c4104962
The following files are available for download:
https://mb.cision.com/Main/19732/4104962/3262998.pdf
Implantica announces positive feedback received from U.S. FDA of the RefluxStopâ'¢ PMA Module 2 submission
https://news.cision.com/implantica/i/logo-transparent-1-8,c3377111
logo transparent 1 8
https://news.cision.com/implantica/i/refluxstop,c3377112
REFLUXSTOP
View original content:https://www.prnewswire.co.uk/news-releases/implantica-announces-positive-feedback-received-from-us-fda-of-the-refluxstop-pma-module-2-submission-302375715.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
40 minutes ago
- Chicago Tribune
Jim Taylor: What my wife's experience with Alzheimer's has taught me
After several unexplained memory slips, there came a day when my wife, Geri, didn't recognize her own face in the mirror. That's when we knew it was time for her to get checked out. It was 2012, and Alzheimer's was a feared diagnosis. At the time, billions of dollars of investments into research and development had failed to produce treatments that could prevent, slow or cure the disease. Getting a definitive diagnosis would be extremely difficult, but the alternative was living with years of the landscape for Alzheimer's diagnosis and treatment has taken a great leap forward. It is increasingly possible to manage the disease and live a fulfilling life. We have reached a historic moment with the FDA's approval of the first blood biomarker tests for Alzheimer's. This long-awaited breakthrough means physicians can now detect early signs of Alzheimer's — which accounts for 70% of all cases of dementia — using a simple blood test that can be done during a regular check-up with your PET scans remain important for confirming a diagnosis, they are only available at specialized centers, typically in urban medical centers, and they are expensive. Blood biomarker tests now offer an easy first step in the diagnostic journey. They provide fast answers for people experiencing memory problems and can even spot early signs of cognitive decline years before symptoms appear. Without these tests, most people have a long, challenging path to wife Geri's path to diagnosis was anything but simple. In 2012, a neurologist confirmed she had mild cognitive impairment, a common precursor to Alzheimer's. It was a life-altering event. Over the next few years, we knew we had to dig deeper into the cause of her condition, to uncover any potential medical options. Eventually we found a clinical trial for an experimental Alzheimer's drug, and she received a PET scan to determine whether she qualified for the trial. Her brain scan detected amyloid plaque, the telltale sign of Alzheimer's. The diagnosis was difficult to face, but it meant we didn't have to struggle with uncertainty. We could act.I understand the fear that surrounds an Alzheimer's diagnosis, but catching it early helps. Changes in the brain begin years before memory problems become noticeable. The earlier the diagnosis, the more options people have. Research shows that anti-amyloid therapies are more effective when administered earlier: In one clinical trial, patients with early Alzheimer's showed 35% slowing of cognitive decline, compared with those on the placebo. These treatments can help people maintain their independence longer and make the most of their lucid was fortunate to participate in a clinical trial that significantly slowed her disease progression. The seven-year trial period was a game-changer for us. The regular infusions were a source of hope as we saw her benefit from the medication. This precious time allowed Geri to develop coping strategies to manage her disease. Together, we traveled across the country giving talks about living with Alzheimer's disease, and Geri needed very little assistance. We cherished this time together — years made possible because we sought answers early. Following the FDA's landmark approval of blood biomarker tests, the next step is making these tests widely available. Hospitals and health care systems across the country should ensure primary care physicians are aware of these tests and understand how to use them. Public education campaigns can raise awareness with people who have concerns about cognitive impairment and their detection gives people meaningful choices, and most importantly it gives people time. Time to benefit from lifestyle changes, participate in groundbreaking clinical trials, and access treatments when they can make the greatest difference. Although facing a potential Alzheimer's diagnosis is daunting, waiting only limits a person's options. If you're concerned that you or a loved one might have signs of cognitive impairment, please don't stay in the dark. Blood biomarker tests offer real hope in a new era of Alzheimer's care. The sooner we embrace these advances, the more precious time we can preserve.
Newsweek
3 hours ago
- Newsweek
Dr Pepper Recall Issued After Sugar Mix Up in Thousands of Cans
A recall has been issued for thousands of cases of Dr Pepper Zero Sugar that were mislabeled and contained the full-sugar product, according to the U.S. Food and Drug Administration (FDA). The products were distributed to retailers in Florida, Georgia, and South Carolina. Newsweek contacted Keurig Dr Pepper, which owns the product in the United States, and PepsiCo, which bottled the beverages, for comment via email outside of regular working hours. Why It Matters This mislabeling poses potential health risks to consumers, particularly for individuals managing conditions like diabetes or those monitoring their sugar intake The FDA has issued a Class II risk classification for the recall, indicating that the consumption of the mislabeled products may cause temporary or medically reversible adverse health consequences. What To Know The FDA said the company-initiated recall affects 19,203 cases of Dr Pepper Zero Sugar 12-fluid ounce cans, sold in 12-pack and 24-pack cartons. The affected cans were produced at a Pepsi bottling facility in Jacksonville, Florida, which is licensed to manufacture Keurig Dr Pepper products, according to the FDA. The affected products have the product code XXXXRS05165, and a best-by date of February 16, 2026. The recall was initiated on May 23, 2025, and the FDA classified it as a Class II recall on June 5, 2025. A can of regular Dr Pepper contains 39 grams of sugar, while the Zero Sugar version has zero grams, but contains the artificial sweeteners aspartame and acesulfame potassium. There were 241 FDA food and beverage recalls in 2024, which was an increase of eight percent from the previous year, according to a report published by the nonprofit Public Interest Research Group. Undeclared allergens or ingredients was the single biggest cause for recalls that year. Last year, Dr Pepper tied with Pepsi to become the second most popular soda in the U.S. after Coca Cola, according to data from Beverage Digest. What Happens Next The FDA and Dr Pepper are working to ensure that all affected products are removed from store shelves promptly. Consumers in the affected states should remain vigilant and check their purchases to ensure they have not bought the mislabeled product.
Yahoo
11 hours ago
- Yahoo
FDA Reveals Which Kinds of Eggs May Be Contaminated with Salmonella
In a June news release, the U.S. Food and Drug Administration revealed that "brown cage-free and brown certified organic eggs" from the August Egg Company have "the potential" to be contaminated with salmonella. The outlet added that the eggs were "sold under multiple different brand names at restaurants and retailers" and should "no longer be available for sale." Those brands are Clover, First Street, Nuaid, O Organics, Marketside, Raleys, Simple Truth, Sun Harvest, and Sunnyside. According to People, over 1.7 million eggs have been recalled in nine states: California, Washington, Nevada, Arizona, Wyoming, New Mexico, Nebraska, Indiana, and Illinois. On June 6, 2025, the Centers for Disease Control and Prevention revealed they were investigating the "multi-state outbreak of salmonella infections." Mayo Clinic states that while some people with salmonella may have no symptoms, most experience a range of symptoms, like abdominal cramps, within 8 to 72 hours. "In some cases, diarrhea can cause severe dehydration and requires prompt medical attention. Life-threatening complications also may develop if the infection spreads beyond the intestines. The risk of getting salmonella infection is higher with travel to countries without clean drinking water and proper sewage disposal." At this time, 21 people have been hospitalized due to infection, according to the FDA. In a statement, the August Egg Company shared, "We believe it is appropriate out of an abundance of caution to conduct this voluntary recall, as consumers may still have these eggs in their homes. It is important to know that when our processing plant identified this concern, we immediately began diverting all eggs from the plant to an egg-breaking facility, which pasteurizes the eggs and kills any pathogens." The company concluded, "We are committed to addressing this matter fully and to implementing all necessary corrective actions to ensure this does not happen again."FDA Reveals Which Kinds of Eggs May Be Contaminated with Salmonella first appeared on Men's Journal on Jun 7, 2025
